Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Ena-DATASET-Genentech-22-08-2012-06:56:27:875-9 - samples

ABSTRACT: Whole genome sequencing of SCLC tumor/normal samples

PROVIDER: EGAD00001000221 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Json Xml

Publications

Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer.

Rudin Charles M CM Durinck Steffen S Stawiski Eric W EW Poirier John T JT Modrusan Zora Z Shames David S DS Bergbower Emily A EA Guan Yinghui Y Shin James J Guillory Joseph J Rivers Celina Sanchez CS Foo Catherine K CK Bhatt Deepali D Stinson Jeremy J Gnad Florian F Haverty Peter M PM Gentleman Robert R Chaudhuri Subhra S Janakiraman Vasantharajan V Jaiswal Bijay S BS Parikh Chaitali C Yuan Wenlin W Zhang Zemin Z Koeppen Hartmut H Wu Thomas D TD Stern Howard M HM Yauch Robert L RL Huffman Kenneth E KE Paskulin Diego D DD Illei Peter B PB Varella-Garcia Marileila M Gazdar Adi F AF de Sauvage Frederic J FJ Bourgon Richard R Minna John D JD Brock Malcolm V MV Seshagiri Somasekar S

Nature genetics 20120902 10

Small-cell lung cancer (SCLC) is an exceptionally aggressive disease with poor prognosis. Here, we obtained exome, transcriptome and copy-number alteration data from approximately 53 samples consisting of 36 primary human SCLC and normal tissue pairs and 17 matched SCLC and lymphoblastoid cell lines. We also obtained data for 4 primary tumors and 23 SCLC cell lines. We identified 22 significantly mutated genes in SCLC, including genes encoding kinases, G protein-coupled receptors and chromatin-m ...[more]

PMID: 22941189

Similar Datasets

ena-DATASET-Genentech-22-08-2012-07:05:26:504-11 - samples

Project description:RNA sequencing of SCLC tumor/normal sample pairs and cell lines

| EGAD00001000223 | EGA

ena-DATASET-Genentech-22-08-2012-07:03:30:871-10 - samples

Project description:Exome capture sequencing of SCLC tumor/normal pairs and cell lines

| EGAD00001000222 | EGA

ena-DATASET-Genentech-10-08-2012-19:45:02:785-17 - samples

Project description:RNA sequencing of colon tumor/normal sample pairs

| EGAD00001000215 | EGA

ena-DATASET-Genentech-10-08-2012-19:54:35:559-18 - samples

Project description:Exome capture sequencing of colon tumor/normal pairs

| EGAD00001000216 | EGA

biomarcha-data-human-serum-08-06-2020

Project description:Serum samples from Chagas disease patients, pre-treatment and 2, 6, 12 and 24 months post-treatment with benznidazole and extracted with methanol. Polar C18 chromatography. PRM analysis of acylcarnitine metabolites.

2020-08-26 | MSV000086025 | MassIVE

miRNA expression profile of SCLC cell lines vs. normal lung

Project description:Aim: To determine the miRNA expression profile of SCLC cell lines vs. normal lung tissue. Keywords: disease state analysis Total RNA isolated from SCLC cell lines H69, HTB-172, HTB-173 and HTB-184 were compared to a mixed RNA sample derived from 6 normal lung tissue samples (fresh surgical material), from 6 tumor-free patients. The same reference sample (normal lung) was used on all 4 microarrays.

2010-07-24 | E-GEOD-8824 | biostudies-arrayexpress

Smad2 and Smad3 binding sites in H345-TbRII cells

Project description:Transforming growth factor (TGF)-beta induces apoptosis of many types of cancer cells and acts as a tumor suppressor. We found lower expression of TGF-beta type II receptor (TbRII) in most of SCLC cells and tissues than in normal lung epithelial cells and normal lung tissues, respectively. In vitro cell growth and in vivo tumor formation were suppressed by TGF-beta-mediated apoptosis when the wild-type TbRII was overexpressed in SCLC cells. We therefore determined Smad2 and Smad3 (Smad2/3) binding sites in a SCLC cell line H345 stably expressing exogenous TbRII (H345-TbRII) to identify target genes of TGF-beta. Smad2 and Smad3 binding sites in H345-TbRII cells were determined by ChIP-seq (one sample analysis, without replicates).

2015-09-15 | E-GEOD-63871 | biostudies-arrayexpress

MHC Peptidomics: HLA-B*27 vs Mamu-B*08

Project description:Indian rhesus macaques are arguably the most reliable animal models in AIDS research. In this species the MHC class I allele Mamu-B*08, among others, is associated with elite control of SIV replication. A similar scenario is observed in humans where the expression of HLA-B*27 or HLA-B*57 has been linked to slow or no progression to AIDS after HIV infection. Despite having large differences in their primary structure, it has been reported that HLA-B*27 and Mamu-B*08 display peptides with sequence similarity. To fine-map the Mamu-B*08 binding motif and assess its similarities with that of HLA-B*27 we affinity purified the peptidomes bound to these MHC class I molecules and analyzed them by LC-MS/MS identifying several thousands of endogenous ligands. Sequence analysis of both sets of peptides revealed a degree of similarity in their binding motifs, especially at peptide position 2 (P2) where arginine was present in the vast majority of ligands of both allotypes. In addition, several differences emerged from this analysis: (i) ligands displayed by Mamu-B*08 tended to be shorter and to have lower molecular weight, (ii) Mamu-B*08 showed a higher preference for glutamine at P2 as a suboptimal binding motif and (iii) the second major anchor position, found at P-omega, was much more restrictive in Mamu-B*08. In this regard, HLA-B*27 bound efficiently peptides with aliphatic, aromatic (including tyrosine) and basic C-terminal residues while Mamu-B*08 preferred peptides with leucine and phenylalanine in this position. These results deepen our understanding of the molecular basis of the presentation of peptides by Mamu-B*08 and can contribute to the detection of novel SIV epitopes restricted by this allotype.

2016-10-07 | PXD004964 | Pride

Isovalerylspiramycin I suppresses small cell lung cancer growth via ROS-mediated DNA damage and ER Stress

Project description:Characterized by rapid progression, early metastasis, and poor prognosis, small cell lung cancer (SCLC) is a highly malignant tumor with limited treatment breakthroughs for nearly 30 years. Exploring alternative approaches is urgent. Tumor cells are more susceptible to ROS triggers for they have a fragile redox balance compared to normal cells. Isovalerylspiramycin I (ISP-I)， purified from a novel macrolide antibiotic carrimycin， inducing accumulation of ROS in several tumor cells, has shown impressive anti-tumor potential. While the specific details and mechanisms of ISP-I's anti-SCLC effects remain unrevealed. We demonstrated that, ISP-I inhibited SCLC growth dose-dependently in vitro and in vivo, with good safety profiles for showing low toxicity to normal cells (MRC-5) and mice at therapeutic doses. Then, we utilized SCLC cell lines H1048 and DMS53 to uncover the anti-SCLC mechanisms of ISP-I. Primarily, ISP-I acted as an inducer of ROS, leading to H1048 and DMS53 cells DNA damage and endoplasmic reticulum (ER) stress through ROS accumulation， ultimately resulting in tumor cells G2/M cell cycle arrest and apoptosis. In conclusion, our study has proven that ISP-I may be a promising therapeutic approach for SCLC with good safety profiles.

2023-10-10 | GSE244376 | GEO

Smad2 and Smad3 binding sites in H345-TbRII cells

2015-09-15 | GSE63871 | GEO